about
How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West EnglandApplying the Sheffield tables to data from general practiceClinical guidelines-the hidden costsNot playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequateImplications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors.From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia.Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable.The primary prevention of coronary heart disease with statins: practice headache or public health?Management of UTI in general practice: a cost effective analysis. A commentary to facilitate an understanding of economic evaluation.The cost-effectiveness of lipid lowering in patients with ischaemic heart disease: an intervention and evaluation in primary care.Peripheral arterial disease: medical care and prevention of complications.Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?A simple computer program for guiding management of cardiovascular risk factors and prescribing.The management of enthusiasm: motives and expectations in cardiovascular medicine.Patients offered treatment for CHD need full information to make decision.Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.Medicalisation, limits to medicine, or never enough money to go around?What do we gain from the sixth coronary heart disease drug?
P2860
Q28221444-FE24B52A-C3C0-4C68-800F-E738ECBCB012Q31301801-AC86FF52-AE71-4914-AF88-22674DFB5696Q33793718-C45BEEB1-9FD9-4F3F-842C-6A4181E140B3Q33795965-D67DB811-0165-401B-A14C-A7911491BD6DQ33849284-570AD793-4F03-4C2B-B1BC-0726EFD57EAAQ33849678-969B185C-7F14-41BF-B65B-37BB10E74B1EQ34219006-C0AC62D3-99F9-4E73-B649-69CF6BB45DD7Q34219017-72B2C884-F16C-42EB-99E0-FB5A90B96DDEQ34219027-C01564BA-4413-4878-B62B-728D679E3B22Q34219038-C5A6EEB2-08D2-4ECC-8E41-FB1EAF2BAA3FQ34714712-D3A50254-2752-478B-8498-B60CDCB6639CQ35580137-8969CEE8-C606-4540-A04C-F918D139FD10Q36266660-B9026568-EB98-43B5-8589-5A890D926D83Q42697998-03020030-83B3-427B-90CE-10BA3DAF0099Q42756355-D69541E7-7315-4043-9FF9-47C43CAEEC56Q42756655-0850896F-4AA2-400D-9CF7-24871D2DDF42Q42777067-98794855-66C1-47EB-B4E5-D775C9BA0928Q43091074-838E92A5-74BA-4FD0-A830-D36FAA3ECD4A
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The use of statins: a case of misleading priorities?
@en
The use of statins: a case of misleading priorities?
@nl
type
label
The use of statins: a case of misleading priorities?
@en
The use of statins: a case of misleading priorities?
@nl
prefLabel
The use of statins: a case of misleading priorities?
@en
The use of statins: a case of misleading priorities?
@nl
P2093
P356
P1433
P1476
The use of statins: a case of misleading priorities?
@en
P2093
Freemantle N
Marchment M
P304
P356
10.1136/BMJ.315.7112.826
P407
P577
1997-10-01T00:00:00Z